Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02083315 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects

A Phase 1 study of Pain, Acute, sponsored by Trevena.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT02083315 is a Phase 1 study of Pain, Acute that has completed, run by Trevena. The registered enrollment target is 30 participants, below the 101-participant average among 31 other Pain, Acute trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02083315, a Phase 1 study of Pain, Acute, has completed, sponsored by Trevena.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study is designed to compare TRV130 to placebo and morphine to learn about its effects on pain relief and side effects.

Conditions Studied

Pain, Acute

Interventions

  • DRUG Placebo
  • DRUG TRV130 1.5 mg
  • DRUG TRV130 3 mg
  • DRUG TRV130 4.5 mg
  • DRUG Morphine 10 mg

Study Locations (1)

Utah

  • CRI Lifetree - Salt Lake City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-07
Est. Completion 2013-08
Phase Phase 1

Sponsor

Trevena

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02083315

The ClinicalTrials.gov registry entry for NCT02083315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 31 other Pain, Acute trials with a reported enrollment target (70% lower). The listed sponsor is Trevena, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain, Acute appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT02083315 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT02083315 about?

NCT02083315 is a clinical study titled "Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects". This study is designed to compare TRV130 to placebo and morphine to learn about its effects on pain relief and side effects.

What is the current status of trial NCT02083315?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-07. Estimated completion is 2013-08.

What conditions does trial NCT02083315 study?

This clinical trial studies the following conditions: Pain, Acute.

What interventions are being tested in trial NCT02083315?

The interventions under investigation include: Placebo (DRUG), TRV130 1.5 mg (DRUG), TRV130 3 mg (DRUG), TRV130 4.5 mg (DRUG), Morphine 10 mg (DRUG).

Who is sponsoring clinical trial NCT02083315?

This trial is sponsored by Trevena, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02083315 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pain, Acute

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pain, Acute

All registered trials for this condition

Utah

All trials with a study site in Utah

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.